Lupartumab amadotin

N/A

Report date: 2024/02/05 13:50:48

Base Information

Drug NameLupartumab amadotin

Drug Alias NameBAY-1129980

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsAnti-LYPD3

TargetsLy6/PLAUR domain-containing protein 3Tubulin

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Develop Information

Active CompaniesBayer AG

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A